After a 3 - to 5-day run-in phase with a ticagrelor 180-mg loading dose ( LD ) followed by a ticagrelor 90-mg twice-daily maintenance dose ( MD ) , aspirin-treated patients ( N = 110 ) with stable coronary artery disease were randomized to continue ticagrelor or switch to prasugrel 10-mg once-daily MD , with or without a 60-mg LD .